The first 50 live births after autologous oocyte vitrification in France

Anzola, Any Beltran; Pauly, Vanessa; Geoffroy-Siraudin, Cendrine; Gervoise-Boyer, Marie-José; Montjean, Debbie; Boyer, Pierre

doi:10.1007/s10815-015-0603-2

Cited by 10 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently it is estimated that around 20 MII oocytes are required per child [14][15][16], which means that only a minority of these patients may benefit from this option. Therefore, IVM matured oocytes in this way may serve as an add-on method to ovarian tissue freezing, especially in young patients and in those centers choosing to excise one whole ovary for fertility preservation, but IVM in this manner cannot be recommended as a single method of fertility preservation.…”

Section: Discussionmentioning

confidence: 99%

Vitrification of in vitro matured oocytes collected from surplus ovarian medulla tissue resulting from fertility preservation of ovarian cortex tissue

Yin

Jiang

Kristensen

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of the study was to investigate the maturation rate of immature oocytes collected from ovarian medulla tissue normally discarded during preparation of ovarian cortical tissue for fertility preservation. Further we evaluated survival of derived MII oocytes following vitrification and warming. Methods 36 patients aged from 8 to 41 years who had one ovary excised for fertility preservation were included. Oocytes were collected from the medulla tissue and matured in vitro 44-48 h followed by vitrification. Number of oocytes collected, the rates of maturation and post-warming survival were assessed. Results On average, 11 immature oocytes were collected per patient. The overall maturation rate was 29 % irrespective of whether the ovary was transported 4-5 h on ice or obtained immediately after oophorectomy. The maturation rate in patients below 20 years of age (55 %) was significantly higher than that of patients aged 20-30 years (29 %) and above 30 years (26 %). The post-warming survival rate was 64 %. No significant relationship was observed between the number of collected oocytes and the age of patients.Conclusions Approximately three MII oocytes were obtained per patient following in vitro maturation (IVM) of immature oocytes collected from medulla tissue, of which two survived vitrification and warming. This approach represents an add-on method to potentially augment the fertility opportunity for cancer patients, especially in young women with cancer where transplantation of cortical tissue may pose a risk of relapse, but the IVM approach is currently too inefficient to be the only method used for fertility preservation.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitrification of in vitro matured oocytes collected from surplus ovarian medulla tissue resulting from fertility preservation of ovarian cortex tissue

Yin

Jiang

Kristensen

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…There are limited studies on the obstetrical and perinatal outcomes of babies born after planned OC. The limited amount of evidence available conclude that neonatal outcomes are similar between fresh and cryopreserved oocytes in infertile patients [31,[44][45][46][47].…”

Section: Obstetrical and Perinatal Outcomesmentioning

confidence: 99%

Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation

Walker

Lanes

Ginsburg

2022

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background The utilization of oocyte cryopreservation (OC) has become popularized with increasing numbers of reproductive-aged patients desiring to maintain fertility for future family building. OC was initially used for fertility preservation in postmenarchal patients prior to gonadotoxic therapies; however, it is now available to patients to circumvent age-related infertility and other diagnoses associated with early loss of ovarian reserve. The primary aim of this paper is to provide a narrative review of the most recent and robust data on the utilization and outcomes of OC in both patient populations. Summary OC results in similar oocyte yield in patients facing gonadotoxic therapies and patients undergoing planned OC. Available data are insufficient to predict the live birth rates or the number of oocytes needed to result in live birth. However, oocyte yield and live birth rates are best among patients < 37.5 years old or with anti-mullerian hormone levels > 1.995 ng/dL, at the time of oocyte retrieval. There is a high ‘no use’ rate (58.9%) in patients using planned OC with 62.5% returning to use frozen oocytes with a spouse. The utilization rate in medical OC patients is < 10%. There is currently no data on the effects of BMI, smoking, or ethnicity on planned OC outcomes. Conclusion It is too early to draw any final conclusions on outcomes of OC in medical OC and planned OC; however, preliminary data supports that utilization of OC in both groups result in preservation of fertility and subsequent live births in patients who return to use their cryopreserved eggs. Higher oocyte yield, with fewer ovarian stimulation cycles, and higher live birth rates are seen in patients who seek OC at younger ages, reinforcing the importance of age on fertility preservation. More studies are needed in medical OC and planned OC to help guide counseling and decision-making in patients seeking these services.

show abstract

“…Compared with fresh oocytes (i.e., those used immediately for in vitro fertilization), previously vitrified oocytes have similar fertilization and ongoing pregnancy rates [128]. The limited studies on obstetrical and perinatal outcomes from pregnancies resulting from OC are reassuring, with no increase in congenital anomalies compared with naturally conceived pregnancies and no difference in maternal/perinatal complications compared with pregnancies resulting from fresh oocytes [97,131,132].…”

Section: Discussionmentioning

confidence: 99%

Oocyte Cryopreservation for Medical and Planned Indications: A Practical Guide and Overview

Han

Seifer

2023

JCM

View full text Add to dashboard Cite

Oocyte cryopreservation (OC) is the process in which ovarian follicles are stimulated, the follicular fluid is retrieved, and mature oocytes are isolated and vitrified. Since the first successful pregnancy utilizing previously cryopreserved oocytes in 1986, OC has become increasingly utilized as an option for future biologic children in patients facing gonadotoxic therapies, such as for the treatment of cancer. Planned OC, also termed elective OC, is growing in popularity as a means to circumvent age-related fertility decline. In this narrative review, we describe both medically indicated and planned OC, focusing on the physiology of ovarian follicular loss, OC technique and risks, timing of when OC should be performed, associated financial considerations, and outcomes.

show abstract

The first 50 live births after autologous oocyte vitrification in France

Abstract: According to our results, newborn health parameters of children conceived in our center by micromanipulation using vitrified/warmed autologous oocytes seem not to be different from children born after micromanipulation on freshly recovered oocytes.

Cited by 10 publications

References 28 publications

Vitrification of in vitro matured oocytes collected from surplus ovarian medulla tissue resulting from fertility preservation of ovarian cortex tissue

Vitrification of in vitro matured oocytes collected from surplus ovarian medulla tissue resulting from fertility preservation of ovarian cortex tissue

Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation

Oocyte Cryopreservation for Medical and Planned Indications: A Practical Guide and Overview

Contact Info

Product

Resources

About